Advancing development of lead candidate BT-101, a potential disease-modifying treatment for Brittle Bone Disease Preparing for Phase III development following promising data showing reduced fractures in affected children STOCKHOLM, Feb. 10, 2026 (GLOBE NEWSWIRE) — BOOST Pharma (“BOOST” or the “Company), a clinical‑stage biopharmaceutical company developing…
Canada News
Kelowna, B.C.’s top RCMP officer says he’s hearing growing frustration from local business owners as crime and social disorder continue to impact the city.…
Lifestyle
TORONTO – Olympic officials made the right call in postponing the Canada-Finland women’s hockey game on Thursday after several players…
Tech & Innovation
At the center of a consequential case about social media liability is a key question: did Meta lie or mislead the public about the safety of…